A number of studies have reported that blockade of TGF-β-ActRII-SMAD2/3 signaling, whether by MSTN inhibition or blockade of ActRII, may have therapeutic benefit in animal models of DMD [36–45]. Here, ACVR2A is linked to Duchenne muscular dystrophy.